Microspheres for the treatment of a prostate hyperplasia by active embolization
First Claim
1. A method of reducing the blood supply to a prostate of a patient to treat a hyperplasia, comprising administering to the prostate of the patient biocompatible, hydrophilic and substantially spherical microspheres comprising(i) an acrylamide, acrylate, or acrylic polymer or copolymer, and(ii) a drug,wherein the drug is associated with the polymer by an ionic interaction, andwherein the diameter of the microspheres ranges from 10 μ
- m to 2000 μ
m.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions.
-
Citations
22 Claims
-
1. A method of reducing the blood supply to a prostate of a patient to treat a hyperplasia, comprising administering to the prostate of the patient biocompatible, hydrophilic and substantially spherical microspheres comprising
(i) an acrylamide, acrylate, or acrylic polymer or copolymer, and (ii) a drug, wherein the drug is associated with the polymer by an ionic interaction, and wherein the diameter of the microspheres ranges from 10 μ
-
13. A method of treating a benign hyperplasia in the prostate of a patient by embolization, said method comprising
administering to the prostate of the patient, biocompatible, hydrophilic and substantially spherical microspheres comprising an acrylamide polymer, wherein the diameter of the microspheres ranges from 10 μ - m to 2000 μ
m. - View Dependent Claims (14, 15, 16, 17, 18)
- m to 2000 μ
-
19. A method of treating a benign hyperplasia in the prostate of a patient by embolization, said method comprising administering to the prostate of the patient, biocompatible and substantially spherical polymer microspheres, wherein the diameter of the microspheres ranges from 10 μ
- m to 2000 μ
m. - View Dependent Claims (20, 21, 22)
- m to 2000 μ
Specification